Eisai Co., Ltd. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/19/2026)
| Balance Sheet | Total Assets | 1,449,113,000,000.00 | ROE | 62.04 % |
| Balance Sheet | Total Equity | 898,992,000,000.00 | ROA | 2.66 % |
| Cashflow | Capital Expenditures | -15,359,000,000.00 | P/FCF | 28.78 |
| Cashflow | Free Cash Flow | 45,964,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 61,323,000,000.00 | P/CF | 21.57 |
| Income | Earnings per Share (diluted) | 136.78 | Div. Yield | 3.41 % |
| Income | Net Income | 38,558,000,000.00 | P/E | 34.30 |
| Income | Shares Outstanding | 281,888,000.00 | P/B | 1.47 |
| Income | Total Revenue | 825,378,000,000.00 | P/S | 1.60 |
Ratios calculated on: 10/14/2026
Company Description
Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's businesses include pharmaceutical business and other business. The Company's segments include Japan (Prescription Medicines, Generics and Diagnostics), Americas (North America, Central and South America), China, Asia (South Korea, Taiwan, Hong Kong, India and ASEAN), EMEA (Europe, the Middle East, Africa and Oceania) and Consumer Healthcare Business-Japan. The Company offers products, which include Halaven, Aricept, Aloxi, Fycompa, Lenvima, Methycobal, BELVIQ, Pariet, LYRICA, HUMIRA, Lunesta, E5501/AKR-501, BAN2401, Chocola BB Products, E2609 and E2006. The Company's consumer healthcare brand containing Vitamin B is Chocola BB Products. The Company offers a range of products, including Chocola BB Plus, a Vitamin B2 preparation for rough skin and stomatitis, and nutritional supplements and energy drinks, which are available for healthcare needs.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.eisai.co.jp
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more